BMC Cancer

Table 4 Univariate analysis of PFS and OS according to clinicopathologic patterns and thymic epithelial markers expression

From: The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma

parameters		PFS		OS
parameters		Median PFS (months)	P	Median OS (months)	P
β5t	+	51.327	0.612	51.527	0.722
β5t	-	61.494	0.612	70.000	0.722
PRSS16	+	70.706	0.078	70.941	0.413
PRSS16	-	41.240	0.078	57.275	0.413
Cathepsin V	+	70.944	0.039	71.167	0.329
Cathepsin V	-	39.560	0.039	56.111	0.329
CD40	+	67.211	0.437	67.421	0.700
CD40	-	47.056	0.437	62.455	0.700
Claudin-4	+	42.532	0.069	58.266	0.352
Claudin-4	-	71.133	0.069	71.133	0.352
AIRE	+	50.582	0.294	63.769	0.323
AIRE	-	58.829	0.294	63.744	0.323
WHO subtype	A, AB, MNT, B1	—	0.006	—	0.040
	B2, B3, TSCC	—		—
Masaoka-Koga stage	I	70.438	0.296	70.688	0.686
Masaoka-Koga stage	II, III, IV	47.451	0.296	59.923	0.686

PFS: Progression-free survival; OS: Overall survival

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com